Printer Friendly

MEDTRONIC ANNOUNCES FIRST U.S. IMPLANT OF THERA(TM) DR PACEMAKER

 MINNEAPOLIS, Jan. 5 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) announced today the first U.S. clinical implant of Thera(TM) DR, a new dual chamber, rate responsive pacemaker designed to restore the heart's rhythm and allow physicians to easily provide therapy required by changing patient conditions.
 The implant was performed Dec. 30, 1993, by Stephen Bailin, M.D., at Mercy Hospital, Des Moines, Iowa. The patient is a 69-year- old woman who presented with sick sinus syndrome and brady/tachy syndrome. She is doing well.
 Before implantation of the Thera DR (her first pacemaker), the patient experienced intermittent atrial fibrillation and asystole, with pauses of up to four seconds. Such a condition requires a pacemaker designed to switch pacing modes to avoid inappropriate tracking of the atrial fibrillation.
 The Thera DR is the full-featured model in a new family of five pacemakers designed to offer a new array of automated features and diagnostic tools allowing physicians to choose a Thera model for virtually any patient condition requiring a pacemaker. All features are designed to save time for physicians while helping them provide the best therapy for their patients.
 Other models in the line include Thera D, Thera VDD, Thera SR, and Thera S. All five have a common user software program, a significant benefit for physicians who work with different types of pacemaker systems.
 Thera DR paces the chambers of the heart as needed to meet the demands of the heart that occur in response to exertion by the patient. When the electrical system of the heart is not working correctly, the upper chambers (atria) and lower chambers (ventricles) may not pump all the blood that's needed. Symptoms may include shortness of breath and fatigue after mild exercise, episodes of dizziness, or fainting.
 The rate responsive, atrial-based pacing of Thera DR ensures that contractions of upper and lower chambers of the heart occur with proper synchronization to let blood flow naturally between the chambers while responding to the patient's metabolic demand. Hemodynamics are restored and cardiac output improved. Consequently, symptoms are reduced while the patient's longevity and feeling of well-being are increased.
 Medtronic, Inc., headquartered in Minneapolis, is the world's leading therapeutic medical device company.
 -0- 1/5/94
 /CONTACT: Dale Beumer, Investor Relations, 612-574-3038, or Dick Reid, Public Relations, 612-574-3052, both of Medtronic/
 (MDT)


CO: Medtronic, Inc. ST: Minnesota IN: MTC SU: PDT

AL-DB -- MN018 -- 9455 01/05/94 15:57 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 5, 1994
Words:402
Previous Article:CONTROL DATA SYSTEMS COMPLETES ACQUISITION OF MICHAEL BUSINESS SYSTEMS IN UNITED KINGDOM
Next Article:UNIVERSAL SEISMIC ASSOCIATES, INC. APPOINTS CFO; DETAILS PRIOR ELECTION OF NEW OUTSIDE DIRECTORS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters